1-(3-O-acetyl-5-S-acetyl-2,5-dideoxy-2-fluoro-5-thio-β-D-arabinofuranosyl)-5-iodocytosine | 105281-18-3

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 1-(3-O-acetyl-5-S-acetyl-2,5-dideoxy-2-fluoro-5-thio-β-D-arabinofuranosyl)-5-iodocytosine
• CAS: 105281-18-3
• 化学式: C₁₃H₁₅FIN₃O₅S
• 分子量: 471.248
• InChiKey: NEIHXVBVLGWCHT-DTHBNOIPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.88
• 重原子数：
  24.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  113.51
• 氢给体数：
  1.0
• 氢受体数：
  9.0

反应信息

• 作为反应物：
  描述：

  1-(3-O-acetyl-5-S-acetyl-2,5-dideoxy-2-fluoro-5-thio-β-D-arabinofuranosyl)-5-iodocytosine 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 1-(2,5-dideoxy-2-fluoro-5-thio-β-D-arabinofuranosyl)-5-iodoacetate
  参考文献：
  名称：

  Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogs of 2'-fluoroarabinosylpyrimidine nucleosides

  摘要：

  In order to determine if modification of the 5'-position reduces or abolishes the antiviral activity of 2'-fluoro-5-iodo-ara-C (FIAC), 2'-fluoro-5-iodo-ara-U (FIAU), or 2'-fluoro-5-methyl-ara-U (FMAU) against human cytomegalovirus (HCMV) and herpes simplex virus (HSV), the 5'-deoxy, 5'-mercapto, and 5'-amino analogues of these nucleosides were prepared. 5'-Deoxy-FIAC and 5'-deoxy-FIAU were prepared by catalytic hydrogenation of 5'-iodo-FIAC and 5'-iodo-FIAU to 5'-deoxy-FAC and 5'-deoxy-FAU, respectively, followed by reiodination at C-5. Reduction of 5'-iodo-FMAU afforded 5'-deoxy-FMAU. These 5'-deoxy nucleosides were found to be inactive against HCMV, indicating that the conversion to 5'-phosphate by the cellular enzyme(s) is a requirement for antiviral activity against this virus. Other 5'-modified (NH2 and SH) analogues were also prepared from 5'-O-tosyl-FIAC and 5'-O-tosyl-FMAU. Treatment of these tosylates with LiN3 in DMF afforded the corresponding 5'-N3 products. Catalytic hydrogenation of 5'-N3-FMAU afforded 5'-NH2-FMAU, whereas 5'-NH2-FIAC was obtained by treatment of 5'-N3-FIAC with Ph3P in pyridine. 5'-Mercapto analogues were prepared by treatment of 5'-O-tosyl-3'-O-acetyl nucleosides with KSAc followed by deacetylation. 5'-NH2-FMAU was the only compound that showed good activity against HSV-1 and HSV-2 in vitro. However, this compound was less potent and had a lower therapeutic index than FMAU.

  DOI：

  10.1021/jm00384a041
• 作为产物：
  描述：

  Toluene-4-sulfonic acid (2R,3R,4S,5R)-5-(4-amino-5-iodo-2-oxo-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-tetrahydro-furan-2-ylmethyl ester 在 吡啶 作用下， 以 丙酮 为溶剂， 反应 19.0h， 生成 1-(3-O-acetyl-5-S-acetyl-2,5-dideoxy-2-fluoro-5-thio-β-D-arabinofuranosyl)-5-iodocytosine
  参考文献：
  名称：

  Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogs of 2'-fluoroarabinosylpyrimidine nucleosides

  摘要：

  In order to determine if modification of the 5'-position reduces or abolishes the antiviral activity of 2'-fluoro-5-iodo-ara-C (FIAC), 2'-fluoro-5-iodo-ara-U (FIAU), or 2'-fluoro-5-methyl-ara-U (FMAU) against human cytomegalovirus (HCMV) and herpes simplex virus (HSV), the 5'-deoxy, 5'-mercapto, and 5'-amino analogues of these nucleosides were prepared. 5'-Deoxy-FIAC and 5'-deoxy-FIAU were prepared by catalytic hydrogenation of 5'-iodo-FIAC and 5'-iodo-FIAU to 5'-deoxy-FAC and 5'-deoxy-FAU, respectively, followed by reiodination at C-5. Reduction of 5'-iodo-FMAU afforded 5'-deoxy-FMAU. These 5'-deoxy nucleosides were found to be inactive against HCMV, indicating that the conversion to 5'-phosphate by the cellular enzyme(s) is a requirement for antiviral activity against this virus. Other 5'-modified (NH2 and SH) analogues were also prepared from 5'-O-tosyl-FIAC and 5'-O-tosyl-FMAU. Treatment of these tosylates with LiN3 in DMF afforded the corresponding 5'-N3 products. Catalytic hydrogenation of 5'-N3-FMAU afforded 5'-NH2-FMAU, whereas 5'-NH2-FIAC was obtained by treatment of 5'-N3-FIAC with Ph3P in pyridine. 5'-Mercapto analogues were prepared by treatment of 5'-O-tosyl-3'-O-acetyl nucleosides with KSAc followed by deacetylation. 5'-NH2-FMAU was the only compound that showed good activity against HSV-1 and HSV-2 in vitro. However, this compound was less potent and had a lower therapeutic index than FMAU.

  DOI：

  10.1021/jm00384a041